Alpha Tau Raises USD 37m
Alpha Tau Medical, an Israeli biotechnology company pioneering the Alpha DaRT® alpha-radiation cancer therapy, has raised USD 36.9 million through a registered direct offering of ordinary shares to an affiliate of US-based Oramed Pharmaceuticals, Inc.
The two companies also formed a three-year strategic partnership, with Oramed set to provide investor and public relations services to support Alpha Tau’s market visibility and growth trajectory.
This deal strengthens Alpha Tau’s capital position and broadens its strategic footprint as it advances cutting-edge oncology treatments.
Meitar advised Alpha Tau on the transaction, with a team led by partners Shachar Hadar and Matthew Rudolph, supported by associate Ezra Ives and intern Noam Mor. Additional counsel was provided by partner Vered Lapushin (tax), partner Dana Yagur, and associate Tal Weintroib (Israel Innovation Authority matters).
